(12) PATENT APPLICATION PUBLICATION

(19) INDIA

(22) Date of filing of Application :29/03/2025

(21) Application No.202521031085 A

(43) Publication Date : 11/04/2025

(54) Title of the invention : Value addition of ellagic acid by transforming it into selenium nanoparticles of ellagic acid with pharmacologically suitable physico-chemical properties, and their therapeutic uses to counteract oxidative stress

(51) International classification :A61K0009140000, A61K0009160000, A23L0033105000, A23K0020100000, A61K0009510000

(86) International Application No :NA
Filing Date :NA

(87) International Publication No : NA

(61) Patent of Addition to Application Number :NA
Filing Date :NA

(62) Divisional to Application Number :NA
Filing Date :NA

(71)**Name of Applicant :**
1)Monika Bhadauria
Address of Applicant :Department of Zoology, Guru Ghasidas University ---------- ----------
2)Satendra Kumar Nirala
Name of Applicant : NA
Address of Applicant : NA
(72)**Name of Inventor :**
1)Monika Bhadauria
Address of Applicant :Department of Zoology, Guru Ghasidas University ---------- ----------
2)Asim Amitabh Sahu
Address of Applicant :Toxicology and Pharmacology Laboratory, Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009 (C.G.) India Bilaspur ---------- ----------
3)Ankita Mukherjee
Address of Applicant :Toxicology and Pharmacology Laboratory, Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009 (C.G.) India Bilaspur ---------- ----------
4)Satendra Kumar Nirala
Address of Applicant :Laboratory of Natural Products, Department of Rural Technology and Social Development, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009 (C.G.) India Bilaspur ---------- ----------

(57) Abstract :
The present investigation includes value addition of ellagic acid by transforming it into selenium nanoparticles of ellagic acid with pharmacologically suitable physico-chemical properties, and their therapeutic uses to counteract oxidative stress with safety profile. The selenium nanoparticles of ellagic acid shown to possess desired pharmacological properties, including particle size less than 100 nm, higher stability, almost spherical shape, free radicals scavenging potential and no observable adverse effect level (NOAEL) up to 4 mg/ kg doses for continuous six days through oral route in rat model.

No. of Pages : 19 No. of Claims : 7